28th Jan 2016 09:22
LONDON (Alliance News) - Respiratory drug development company Skyepharma PLC on Thursday said it has entered a deal with Sanofi Winthrop Industrie and Mundipharma International Corp Ltd for the pair to be development and marketing partners for the Flutiform asthma treatment in Mexico, Central and South America.
Mundipharma's network already has development, licensing and marketing rights for most markets outside Japan and the US and will now add the Mexican and Americas licences to the deal.
No financial details were disclosed on the partnership. Mundipharma is a unit of Sanofi SA, the French drugmaker.
"Mundipharma has made very good progress with flutiform in markets around the world and we welcome the opportunity to further extend our partnership with its international network," said Skyepharma Chief Executive Peter Grant.
Shares in Skyepharma were down 0.1% to 391.75 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L